Dr. Doug Hawkins, Associate Professor of Pediatrics at Seattle Children’s Hospital, discusses the use of fluorodeoxyglucose PET imaging in measuring patients’ responses to chemotherapy.
References and Resources
Berkowitz A et al. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun. 2008 Jun;29(6):521-6.
El-Haddad G et al. Normal variants in [18F]-fluorodeoxyglucose PET imaging. Radiol Clin North Am. 2004 Nov;42(6):1063-81, viii.
Nieweg OE et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med. 1996 Feb;37(2):257-61
